| Drug Name |
Etonogestrel |
| Drug ID |
BADD_D00852 |
| Description |
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692] |
| Indications and Usage |
Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990]
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698] |
| Marketing Status |
approved; investigational |
| ATC Code |
G03AC08 |
| DrugBank ID |
DB00294
|
| KEGG ID |
D04104
|
| MeSH ID |
C044815
|
| PubChem ID |
6917715
|
| TTD Drug ID |
D02KIU
|
| NDC Product Code |
64918-1500; 78206-145; 71161-147; 63190-0260; 45541-1192; 60870-0475; 63190-0480; 64918-1906; 65089-0053 |
| UNII |
304GTH6RNH
|
| Synonyms |
etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon |
